Sign In

Greg Brown

Chief Executive Officer at Memgen

Gregory B. Brown, M.D., is the Chief Executive Officer of Memgen, a private biotechnology company focused on developing innovative immuno-oncology drugs. He was appointed to this position on March 17, 2020, and has been a member of Memgen's board of directors since March 2007.12 Under his leadership, Memgen aims to advance its lead program into clinical trials, leveraging promising preclinical data to benefit cancer patients with limited treatment options.1

Professional Background

Dr. Brown has a diverse background that spans the fields of medicine, finance, and biotechnology:

  • Medical Training: He is trained as a thoracic and vascular surgeon and has practiced in a community setting. His medical education includes an M.D. from SUNY Upstate Medical Center and a BA from Yale University.23
  • Investment Experience: He co-founded HealthCare Royalty Partners (HCR), where he currently serves as Vice Chairman and a member of the Senior Advisor Board. His previous roles include being a partner at Paul Capital Partners and co-head of investment banking at Adams, Harkness & Hill.13
  • Board Memberships: Dr. Brown has served on the boards of numerous public and private life science companies, including Aquestive Therapeutics and Caladrius Biosciences.12

Education

Dr. Brown holds an MBA from Harvard Business School, complementing his medical degree and undergraduate education at Yale.23

Personal Life

He is married to Iris DeMent, an accomplished singer-songwriter.

Dr. Brown's extensive experience in both clinical practice and the financial aspects of biotechnology positions him as a significant leader in the field, driving Memgen's mission forward in the competitive landscape of cancer therapeutics.

Highlights

Jan 13 · en.wikipedia.org
Greg Brown (businessman) - Wikipedia
Greg Brown - Motorola Solutions
Greg Brown - Motorola Solutions
Nov 30 · Business Wire
Memgen Reports Results From Its First-In-Human Clinical Trial of ... - Business Wire
Memgen Reports Results From Its First-In-Human Clinical Trial of ... - Business Wire
Nov 30 · Yahoo Finance
Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory to Checkpoint Inhibitors at SITC 2022 - Yahoo Finance
Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory
Greg Brown | Board Member,Management - Udemy
Mar 17 · memgenbio.com
Memgen Appoints Gregory Brown as Chief Executive Officer

Related Questions

What are Greg Brown's key achievements at Memgen?
How did Greg Brown transition from a surgeon to a CEO in the biotech industry?
What is the significance of Greg Brown's role at Healthcare Royalty Partners?
How has Greg Brown's leadership impacted Memgen's drug development?
What are the main challenges Greg Brown has faced at Memgen?
Greg Brown
Greg Brown, photo 1
Greg Brown, photo 2
Add to my network

Location

Houston, Texas